Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing

• DOI: 10.1007/s10147-024-02683-0
• Publication Date: 2025-02-07T17:36:32Z
• Authors: Shin Kobayashi; Yoshiaki Nakamura; Tadayoshi Hashimoto; Hideaki Bando; Eiji Oki; Takahiro Karasaki; Hidehito Horinouchi; Yukinori Ozaki; Hiroji Iwata; Taigo Kato; Hideaki Miyake; Akihiro Ohba; Masafumi Ikeda; Tatsuyuki Chiyoda; Kosei Hasegawa; Takao Fujisawa; Kazuto Matsuura; Kenjiro Namikawa; Shugo Yajima; Takayuki Yoshino; Kiyoshi Hasegawa
• Keywords: Surgical oncology; Clinical Oncology; Minimal Residual Disease; Precision oncology; Position paper

Although the 5-year relative survival rates for resectable solid tumors have improved over past few years, risk of postoperative recurrence necessitates effective monitoring strategies. Recent advancements in molecular residual disease (MRD) testing based on circulating tumor DNA (ctDNA) analysis shown considerable promise context predicting recurrence; however, significant barriers to widespread clinical implementation remain-mainly, low awareness among healthcare professionals, high costs, and lack standardized assays comprehensive evidence. This position paper, led by Japan Society Clinical Oncology, aims establish a common framework appropriate use MRD type-agnostic manner. It synthesizes currently available evidence, reviews region-specific trends, addresses critical questions related testing, offers recommendations guide biotechnology pharmaceutical companies, regulatory authorities. These were developed voting process involving 15 expert members, ensuring consensus-driven approach. findings underscore importance collaborative efforts various stakeholders enhancing utility testing. project aimed foster consensus provide clear guidelines support advancement precision medicine oncology improve patient outcomes perioperative care.